Inflammatory markers study for newly diagnosed B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at inflammatory markers in the blood of people newly diagnosed with B-cell neoplasms (a group of blood cancers and related disorders). It aims to better understand how these markers relate to the disease and may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with a B-cell neoplasm (a type of blood cancer or related disorder).
- Your diagnosis must be one of the specific types listed, such as certain lymphomas, leukemias, or multiple myeloma.
- You must be 18 years old or older.
- This trial is not for people who have been diagnosed with a B-cell neoplasm before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines specific markers (PD-L1 and CD276) on blood cancer cells in newly diagnosed patients with B-cell leukemias or lymphomas. Understanding these markers may help doctors better understand your cancer and develop better treatments.
This study looks at two proteins on cancer cells (CD305 and CD85d) to better understand types of B-cell blood cancers. Results may help doctors tailor future treatments.
This study looks at inflammation-related lab markers in people with “Ph-negative” myeloproliferative neoplasms (like PV, ET, or PMF) to see how they relate to outcomes and response to treatment. It’s observational, meaning it gathers information from medical records without testing a new treatment.
This study looks at how certain blood tests (like CRP, albumin, and their ratios) might help predict how well treatment works for newly diagnosed DLBCL. If you are getting R-CHOP, this trial could help doctors better understand your response to therapy.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
This study looks for tumor “signatures” (including tiny RNA molecules, or miRNA) to predict outcomes in people with relapsed or resistant diffuse large B‑cell lymphoma (DLBCL). Your tissue samples help researchers see which patients may benefit from standard chemotherapy plus antibody treatment.
Hear when a new B-cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.